Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Summary

Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.

Conditions

• Multiple Myeloma
• Light Chain Nephropathy
• Acute Kidney Injury

Interventions

PROCEDURE

Plasma exchange

Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy

DRUG

Daratumumab

Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy

Sponsors & Collaborators

• Janssen, LP

  collaborator INDUSTRY

• Baystate Health

  collaborator OTHER

• Boston Medical Center

  collaborator OTHER

• Dana-Farber Cancer Institute

  collaborator OTHER

• Massachusetts General Hospital

  collaborator OTHER

• Mayo Clinic

  collaborator OTHER

• M.D. Anderson Cancer Center

  collaborator OTHER

• Medical University of South Carolina

  collaborator OTHER

• H. Lee Moffitt Cancer Center and Research Institute

  collaborator OTHER

• Icahn School of Medicine at Mount Sinai

  collaborator OTHER

• Northwell Health

  collaborator OTHER

• Ochsner Health System

  collaborator OTHER

• Ohio State University

  collaborator OTHER

• Stanford University

  collaborator OTHER

• Texas Medical Center

  collaborator UNKNOWN

• Thomas Jefferson University

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• University of Chicago

  collaborator OTHER

• University of Colorado Health

  collaborator OTHER

• University of Minnesota

  collaborator OTHER

• University of New Mexico

  collaborator OTHER

• University of Pennsylvania

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• University of Virginia

  collaborator OTHER

• University of Washington

  collaborator OTHER

• Brigham and Women's Hospital

  lead OTHER

Principal Investigators

• Shruti Gupta, MD · Brigham and Women's Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-06-01

Primary Completion

2026-06-01

Completion

2026-06-01

FDA Drug

Yes

Countries

• United States

Study Locations